Proteo Inc (PTEO) 0.3000 $PTEO Proteo, Inc. / Proteo

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Proteo Inc (PTEO) 0.3000 $PTEO

Proteo, Inc. / Proteo Biotech AG: Elafin Combined with Cyclosporine Promises to Overcome Limitations of Cyclosporine for Preventing Irreversible Damage to Transplanted Organs.
Business Wire - Thu Mar 12, 8:00AM CDT
Proteo, Inc. (OTCQB: PTEO) and its wholly-owned subsidiary Proteo Biotech AG today announced the publication of new results from a group of researchers lead by Mark Nicolls at the Stanford School of Medicine which demonstrate that Elafin and cyclosporine A act synergistically to prevent the development of irreversible damage to transplanted lung tissue in an animal model.

Ischemia Reperfusion Injury - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6pp4ft/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Pharming Group N.V. - BioLineRx, Ltd. - Silence Therapeutics plc - Proteo, Inc. - Scynexis, Inc. - Prolong Pharmaceuticals - Trophos SA - Curatis Pharma GmbH - Alligator Bioscience AB - Opsona Therapeutics Ltd. - PledPharma AB - Zealand Pharma A/S - Omeros Corporation - Bolder Biotechnology, Inc. - Adienne S.r.l. - Genextra S.p.a. - KAEL-GemVax Co., Ltd. - Ischemix - APT Therapeutics, Inc. - Peptinnovate Limited For more information visit http://www.researchandmarkets.com/research/6pp4ft/ischemia
OMER: 20.99 (+0.11)

Proteo Biotech AG Expands Management Board
Business Wire - Fri Dec 05, 4:00AM CST
Proteo, Inc. (OTCQB: PTEO) and its wholly-owned subsidiary Proteo Biotech AG today announced that the company strengthens its Management Board. The Supervisory Board of Proteo Biotech AG has appointed Dr. Juergen Paal as a new member of the company's Management Board, effective from Dec 1st, 2014. In this leadership role as Proteo Biotech AG's new Chief Operating Officer, he will be responsible for Proteo's clinical development program, product launch preparation, business development and partnering initiatives.

Proteo, Inc. / Proteo Biotech AG: Final Analysis of the Phase II Clinical Study on Elafin in Coronary Artery Bypass Surgery Completed
Business Wire - Fri Nov 21, 5:30AM CST
Proteo, Inc. (OTCQB: PTEO) and its wholly-owned subsidiary Proteo Biotech AG today announced that the NHS Lothian's Edinburgh Heart Centre has completed final analysis of data from the investigator initiated Phase II clinical trial (EMPIRE study) with Proteo's drug candidate Elafin for prevention of myocardial injury after coronary artery bypass surgery (CABG). The EMPIRE study was designed as a randomized, double-blinded and placebo-controlled study on 87 patients to investigate the therapeutic potential of a single preoperative Elafin dose on postoperative myocardial injury. This was measured by troponin I plasma concentration which is released by damaged heart muscle cells and its plasma concentration correlates with overall damage of the heart muscle. It was assumed that this treatment would lower the troponin I release over 48 hours. Publication of the EMPIRE study results is planned in a peer reviewed journal.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Omneky Outshines Competitors in AI Ad Scoring

Updated Category News Views 35

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Continue Reading
Quark Baby's Milk Warmer Debut at Vancouver & Dubai

Updated Category News Views 29

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...

Continue Reading
TechCrunch Disrupt 2026: NYSE and Snowflake Highlights

Updated Category News Views 31

Ever noticed how the air vibrates just a bit more when major players like NYSE and Snowflake start shaking hands at big-league events like TechCrunch Disrupt? You'd better believe we're seeing a fresh brew of opportunities and challenges in the market as these titans lock horns and share insights. It's no small feat when the financial nerve center partners into the tech...

Continue Reading
Laars Welcomes Women in Manufacturing to Facility Tour

Updated Category News Views 14

Opening Doors and Minds in Manufacturing On October 15, Laars Heating Systems throws wide open its Rochester, N.H., facility to a group that's rewriting the rulebook: women in manufacturing. It's not just another day in the life of assembly lines and engineering desks, folks. This is about giving a platform to those often sidelined in the field of boilers and water...

Continue Reading
Trial for Former OB/GYN Arthur Park Begins in Bakersfield

Updated Category News Views 12

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Continue Reading
Simple Home Upgrades That Boost Value Fast

Updated Category News Views 17

Transform Your Home's Curb Appeal Without Breaking The Bank Every homeowner knows that feeling when you look at your house one day and think, "This could use a little something." Say you're strolling through a neighborhood in Fulton, N.Y., and notice a gem. It's not a brand new build, but it gleams with character. You bet it's had a few smart touches that could apply...

Continue Reading
Honeywell Aerospace Faces Legal Turbulence in Fraud Case

Updated Category News Views 13

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

Continue Reading
Paradigm Therapeutics: A Beacon in Rare Diseases

Updated Category News Views 4

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

Continue Reading
Fluence Energy Faces Major Lawsuit Amid $3B Loss

Updated Category News Views 19

Securities Class Action: A Storm Brewing Just when you think you've got a grip on the market, a sharp right hook can come out of nowhere. Fluence Energy (NASDAQ:FLNC) is dealing with one of those punches now, getting dragged into the courtroom over claims they fudged financial lines. They hail innovation in energy storage, but shareholders are left shaking in their boots...

Continue Reading
Coventry's Jacobs Joins European Life Settlement Execs

Updated Category News Views 31

Neal Jacobs Steps Up in Life Settlements Coventry has added another feather to its cap with Neal Jacobs, their Senior Managing Director of Capital Markets, joining the Executive Committee of the European Life Settlement Association (ELSA). Elected at ELSA's Annual General Meeting on September 15, 2026, Jacobs brings a wealth of experience that promises to bolster the...

Continue Reading

Top 5 Most Recently Viewed Articles

NEIRO Expands with Chainlink and Cross-Chain Features

Updated Category News Views 132

NEIRO Expands with New Partnerships In a strategic move, NEIRO, a sister token of Dogecoin, has announced significant partnerships aimed at leveraging the current meme coin supercycle. The integration of Chainlink Price Feeds on Ethereum signals a robust approach to establishing secure markets for its $NEIRO token. Chainlink Integration for Enhanced Security By adopting...

Continue Reading
Sunflower Therapeutics Secures $3 Million SAFE for Future Growth

Updated Category News Views 368

Sunflower Therapeutics Secures Oversubscription of $3 Million SAFE Sunflower Therapeutics, a public benefit corporation dedicated to improving global protein manufacturing, recently announced the successful oversubscription of a $3 million Simple Agreement for Future Equity (SAFE). This achievement illustrates strong investor confidence in the company's mission to enhance...

Continue Reading
Canada and Manitoba's Historic Agreement on Language Education

Updated Category News Views 228

Significant Investment in Language Education The Government of Canada is making a substantial investment of over $72 million to enhance French language education in Manitoba. This funding is dedicated to both French as a minority language and French as a second language education, ensuring quality learning opportunities from preschool through to post-secondary education....

Continue Reading
RTX's Innovative Seating Solutions Transform Airline Experience

Updated Category News Views 344

RTX's Innovative Seating Solutions Transform Airline Experience Imaginative approach refreshes cabins, reduces waste and maximizes customer investment Collins Aerospace, an RTX (NYSE: RTX) business, is showcasing revolutionary aftermarket seating concepts that offer contemporary upgraded solutions for airlines utilizing Collins' Pinnacle main cabin seats. This initiative...

Continue Reading
Eli Lilly Snags Global Deal for Hanmi's Drug Candidate

Updated Category News Views 16

Pivotal Deal for Hanmi's Sonefpeglutide Picture this: a bustling boardroom in Seoul where Hanmi is laying out its cutting-edge innovation on the table. Today, they're not just making moves—they're making headlines. Hanmi has signed a licensing agreement with Eli Lilly, the American pharma heavyweight, for their promising biologic drug sonefpeglutide. If you're in this...

Continue Reading